Satoshi Ide
Overview
Explore the profile of Satoshi Ide including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
434
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang Y, Ide S, Kato A, Yoshida K, Jiang C, Zhai P
Sci Adv
. 2025 Feb;
11(9):eadr9353.
PMID: 40009665
Earthquakes may seem random, but are often concentrated in some localized areas. Thus, they are likely controlled by fault materials and stress heterogeneity, which are little understood. Here, we provide...
2.
Hayakawa K, Saito S, Miyoshi-Akiyama T, Fukui Y, Takemoto N, Hashimoto T, et al.
J Infect Chemother
. 2024 Jun;
30(12):1274-1279.
PMID: 38879077
Background: Cefmetazole (CMZ) is a carbapenem-sparing option in the treatment of extended-spectrum beta-lactamase (ESBL)-producing bacterial infection. In this pilot study, we aimed to compare the effects of antimicrobial treatment (meropenem...
3.
Ide S, Beroza G
Proc Natl Acad Sci U S A
. 2023 Jul;
120(32):e2222102120.
PMID: 37523541
The scaling law for slow earthquakes, which is a linear relationship between seismic moment and duration, was proposed 15 y ago and initiated a debate on the difference in physical...
4.
Clinical outcomes and epidemiological characteristics of bacteremia in the older Japanese population
Nakamura K, Hayakawa K, Tsuzuki S, Ide S, Nomoto H, Nakamoto T, et al.
J Infect Chemother
. 2023 Jun;
29(10):971-977.
PMID: 37355094
Background: The characteristics and clinical consequences of bacteremia in older people, who are highly susceptible to infections, need to be clarified. This study aimed to determine the epidemiological characteristics, prognosis,...
5.
Ide S, Ishikane M, Aoyagi K, Ono A, Asai Y, Tsuzuki S, et al.
PLoS One
. 2023 Jun;
18(6):e0287297.
PMID: 37347735
Macrolide usage in Japan exceeds that in Europe and the United States. Investigating the actual conditions in which macrolides are used is important for identifying further interventions for appropriate antimicrobial...
6.
Nomoto H, Yamamoto K, Isaka E, Miyazato Y, Suzuki T, Maruki T, et al.
J Infect Chemother
. 2022 Sep;
29(1):15-19.
PMID: 36089257
Introduction: Anterior nasal sampling (AN) might be more convenient for patients than NP sampling to diagnose coronavirus disease. This study investigated the feasibility of rapid antigen tests for AN sampling,...
7.
Hayama H, Ide S, Kitami Y, Hara H, Kutsuna S, Hiroi Y
Glob Health Med
. 2022 Mar;
4(1):61-63.
PMID: 35291195
Coronavirus disease (COVID-19) causes myocardial injury by inducing a cytokine storm in severe cases. Studies have reported that myocardial injury persists for a prolonged period during COVID-19 recovery, and cardiac...
8.
Ide S, Kurozumi A, Takeshige A, Shimomura A, Watanabe R, Inagaki T
IDCases
. 2022 Mar;
28:e01475.
PMID: 35284230
No abstract available.
9.
Suzuki M, Hayakawa K, Asai Y, Matsunaga N, Terada M, Ohtsu H, et al.
Jpn J Infect Dis
. 2022 Mar;
75(4):419-422.
PMID: 35228500
The detection of other pathogens in patients with hospitalized coronavirus disease (COVID-19) are not frequent. Considering that data from Japan are limited, we conducted an observational study including patients with...
10.
Ide S, Saito S, Akazawa T, Furuya T, Masuda J, Nagashima M, et al.
IDCases
. 2021 Nov;
26:e01343.
PMID: 34804800
Remdesivir is an antiviral drug that results in clinical improvement after five days of treatment and accelerates recovery by 31%. No studies have discussed the pharmacokinetic analysis of remdesivir in...